Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Anti Inflammatory Peptide Market

ID: MRFR/HC/38852-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Anti-inflammatory Peptide Market Research Report By Mechanism of Action (NF-B Inhibition, JAK/STAT Inhibition, Interleukin Inhibition, TNF- Inhibition), By Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Multiple Sclerosis), By Source (Animal Origin, Plant Origin, Microbial Origin), By Route of Administration (Injections, Oral, Topical) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Anti Inflammatory Peptide Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Mechanism of Action (USD Billion)
  49.     4.1.1 NF-B Inhibition
  50.     4.1.2 JAK/STAT Inhibition
  51.     4.1.3 Interleukin Inhibition
  52.     4.1.4 TNF- Inhibition
  53.   4.2 Healthcare, BY Indication (USD Billion)
  54.     4.2.1 Rheumatoid Arthritis
  55.     4.2.2 Osteoarthritis
  56.     4.2.3 Gout
  57.     4.2.4 Multiple Sclerosis
  58.   4.3 Healthcare, BY Source (USD Billion)
  59.     4.3.1 Animal Origin
  60.     4.3.2 Plant Origin
  61.     4.3.3 Microbial Origin
  62.   4.4 Healthcare, BY Route of Administration (USD Billion)
  63.     4.4.1 Injections
  64.     4.4.2 Oral
  65.     4.4.3 Topical
  66.   4.5 Healthcare, BY Region (USD Billion)
  67.     4.5.1 North America
  68.       4.5.1.1 US
  69.       4.5.1.2 Canada
  70.     4.5.2 Europe
  71.       4.5.2.1 Germany
  72.       4.5.2.2 UK
  73.       4.5.2.3 France
  74.       4.5.2.4 Russia
  75.       4.5.2.5 Italy
  76.       4.5.2.6 Spain
  77.       4.5.2.7 Rest of Europe
  78.     4.5.3 APAC
  79.       4.5.3.1 China
  80.       4.5.3.2 India
  81.       4.5.3.3 Japan
  82.       4.5.3.4 South Korea
  83.       4.5.3.5 Malaysia
  84.       4.5.3.6 Thailand
  85.       4.5.3.7 Indonesia
  86.       4.5.3.8 Rest of APAC
  87.     4.5.4 South America
  88.       4.5.4.1 Brazil
  89.       4.5.4.2 Mexico
  90.       4.5.4.3 Argentina
  91.       4.5.4.4 Rest of South America
  92.     4.5.5 MEA
  93.       4.5.5.1 GCC Countries
  94.       4.5.5.2 South Africa
  95.       4.5.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 Boehringer Ingelheim (DE)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Novartis (CH)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Pfizer (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Amgen (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Eli Lilly and Company (US)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 Bristol-Myers Squibb (US)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Sanofi (FR)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Merck & Co. (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 AbbVie (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY MECHANISM OF ACTION
  173.   6.4 US MARKET ANALYSIS BY INDICATION
  174.   6.5 US MARKET ANALYSIS BY SOURCE
  175.   6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  176.   6.7 CANADA MARKET ANALYSIS BY MECHANISM OF ACTION
  177.   6.8 CANADA MARKET ANALYSIS BY INDICATION
  178.   6.9 CANADA MARKET ANALYSIS BY SOURCE
  179.   6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  180.   6.11 EUROPE MARKET ANALYSIS
  181.   6.12 GERMANY MARKET ANALYSIS BY MECHANISM OF ACTION
  182.   6.13 GERMANY MARKET ANALYSIS BY INDICATION
  183.   6.14 GERMANY MARKET ANALYSIS BY SOURCE
  184.   6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  185.   6.16 UK MARKET ANALYSIS BY MECHANISM OF ACTION
  186.   6.17 UK MARKET ANALYSIS BY INDICATION
  187.   6.18 UK MARKET ANALYSIS BY SOURCE
  188.   6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  189.   6.20 FRANCE MARKET ANALYSIS BY MECHANISM OF ACTION
  190.   6.21 FRANCE MARKET ANALYSIS BY INDICATION
  191.   6.22 FRANCE MARKET ANALYSIS BY SOURCE
  192.   6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  193.   6.24 RUSSIA MARKET ANALYSIS BY MECHANISM OF ACTION
  194.   6.25 RUSSIA MARKET ANALYSIS BY INDICATION
  195.   6.26 RUSSIA MARKET ANALYSIS BY SOURCE
  196.   6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  197.   6.28 ITALY MARKET ANALYSIS BY MECHANISM OF ACTION
  198.   6.29 ITALY MARKET ANALYSIS BY INDICATION
  199.   6.30 ITALY MARKET ANALYSIS BY SOURCE
  200.   6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  201.   6.32 SPAIN MARKET ANALYSIS BY MECHANISM OF ACTION
  202.   6.33 SPAIN MARKET ANALYSIS BY INDICATION
  203.   6.34 SPAIN MARKET ANALYSIS BY SOURCE
  204.   6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  205.   6.36 REST OF EUROPE MARKET ANALYSIS BY MECHANISM OF ACTION
  206.   6.37 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  207.   6.38 REST OF EUROPE MARKET ANALYSIS BY SOURCE
  208.   6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  209.   6.40 APAC MARKET ANALYSIS
  210.   6.41 CHINA MARKET ANALYSIS BY MECHANISM OF ACTION
  211.   6.42 CHINA MARKET ANALYSIS BY INDICATION
  212.   6.43 CHINA MARKET ANALYSIS BY SOURCE
  213.   6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  214.   6.45 INDIA MARKET ANALYSIS BY MECHANISM OF ACTION
  215.   6.46 INDIA MARKET ANALYSIS BY INDICATION
  216.   6.47 INDIA MARKET ANALYSIS BY SOURCE
  217.   6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  218.   6.49 JAPAN MARKET ANALYSIS BY MECHANISM OF ACTION
  219.   6.50 JAPAN MARKET ANALYSIS BY INDICATION
  220.   6.51 JAPAN MARKET ANALYSIS BY SOURCE
  221.   6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  222.   6.53 SOUTH KOREA MARKET ANALYSIS BY MECHANISM OF ACTION
  223.   6.54 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  224.   6.55 SOUTH KOREA MARKET ANALYSIS BY SOURCE
  225.   6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  226.   6.57 MALAYSIA MARKET ANALYSIS BY MECHANISM OF ACTION
  227.   6.58 MALAYSIA MARKET ANALYSIS BY INDICATION
  228.   6.59 MALAYSIA MARKET ANALYSIS BY SOURCE
  229.   6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  230.   6.61 THAILAND MARKET ANALYSIS BY MECHANISM OF ACTION
  231.   6.62 THAILAND MARKET ANALYSIS BY INDICATION
  232.   6.63 THAILAND MARKET ANALYSIS BY SOURCE
  233.   6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  234.   6.65 INDONESIA MARKET ANALYSIS BY MECHANISM OF ACTION
  235.   6.66 INDONESIA MARKET ANALYSIS BY INDICATION
  236.   6.67 INDONESIA MARKET ANALYSIS BY SOURCE
  237.   6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  238.   6.69 REST OF APAC MARKET ANALYSIS BY MECHANISM OF ACTION
  239.   6.70 REST OF APAC MARKET ANALYSIS BY INDICATION
  240.   6.71 REST OF APAC MARKET ANALYSIS BY SOURCE
  241.   6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  242.   6.73 SOUTH AMERICA MARKET ANALYSIS
  243.   6.74 BRAZIL MARKET ANALYSIS BY MECHANISM OF ACTION
  244.   6.75 BRAZIL MARKET ANALYSIS BY INDICATION
  245.   6.76 BRAZIL MARKET ANALYSIS BY SOURCE
  246.   6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  247.   6.78 MEXICO MARKET ANALYSIS BY MECHANISM OF ACTION
  248.   6.79 MEXICO MARKET ANALYSIS BY INDICATION
  249.   6.80 MEXICO MARKET ANALYSIS BY SOURCE
  250.   6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  251.   6.82 ARGENTINA MARKET ANALYSIS BY MECHANISM OF ACTION
  252.   6.83 ARGENTINA MARKET ANALYSIS BY INDICATION
  253.   6.84 ARGENTINA MARKET ANALYSIS BY SOURCE
  254.   6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  255.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY MECHANISM OF ACTION
  256.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  257.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOURCE
  258.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  259.   6.90 MEA MARKET ANALYSIS
  260.   6.91 GCC COUNTRIES MARKET ANALYSIS BY MECHANISM OF ACTION
  261.   6.92 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  262.   6.93 GCC COUNTRIES MARKET ANALYSIS BY SOURCE
  263.   6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  264.   6.95 SOUTH AFRICA MARKET ANALYSIS BY MECHANISM OF ACTION
  265.   6.96 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  266.   6.97 SOUTH AFRICA MARKET ANALYSIS BY SOURCE
  267.   6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  268.   6.99 REST OF MEA MARKET ANALYSIS BY MECHANISM OF ACTION
  269.   6.100 REST OF MEA MARKET ANALYSIS BY INDICATION
  270.   6.101 REST OF MEA MARKET ANALYSIS BY SOURCE
  271.   6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  272.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  273.   6.104 RESEARCH PROCESS OF MRFR
  274.   6.105 DRO ANALYSIS OF HEALTHCARE
  275.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  276.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  277.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  278.   6.109 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
  279.   6.110 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
  280.   6.111 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  281.   6.112 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  282.   6.113 HEALTHCARE, BY SOURCE, 2024 (% SHARE)
  283.   6.114 HEALTHCARE, BY SOURCE, 2024 TO 2035 (USD Billion)
  284.   6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  285.   6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  286.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  287. 7 LIST OF TABLES
  288.   7.1 LIST OF ASSUMPTIONS
  289.     7.1.1
  290.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  291.     7.2.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  292.     7.2.2 BY INDICATION, 2025-2035 (USD Billion)
  293.     7.2.3 BY SOURCE, 2025-2035 (USD Billion)
  294.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  295.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  296.     7.3.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  297.     7.3.2 BY INDICATION, 2025-2035 (USD Billion)
  298.     7.3.3 BY SOURCE, 2025-2035 (USD Billion)
  299.     7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  300.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  301.     7.4.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  302.     7.4.2 BY INDICATION, 2025-2035 (USD Billion)
  303.     7.4.3 BY SOURCE, 2025-2035 (USD Billion)
  304.     7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  305.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.5.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  307.     7.5.2 BY INDICATION, 2025-2035 (USD Billion)
  308.     7.5.3 BY SOURCE, 2025-2035 (USD Billion)
  309.     7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  310.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  311.     7.6.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  312.     7.6.2 BY INDICATION, 2025-2035 (USD Billion)
  313.     7.6.3 BY SOURCE, 2025-2035 (USD Billion)
  314.     7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  315.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  316.     7.7.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  317.     7.7.2 BY INDICATION, 2025-2035 (USD Billion)
  318.     7.7.3 BY SOURCE, 2025-2035 (USD Billion)
  319.     7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  320.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  321.     7.8.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  322.     7.8.2 BY INDICATION, 2025-2035 (USD Billion)
  323.     7.8.3 BY SOURCE, 2025-2035 (USD Billion)
  324.     7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  325.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  326.     7.9.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  327.     7.9.2 BY INDICATION, 2025-2035 (USD Billion)
  328.     7.9.3 BY SOURCE, 2025-2035 (USD Billion)
  329.     7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  330.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  331.     7.10.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  332.     7.10.2 BY INDICATION, 2025-2035 (USD Billion)
  333.     7.10.3 BY SOURCE, 2025-2035 (USD Billion)
  334.     7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  335.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  336.     7.11.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  337.     7.11.2 BY INDICATION, 2025-2035 (USD Billion)
  338.     7.11.3 BY SOURCE, 2025-2035 (USD Billion)
  339.     7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  340.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  341.     7.12.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  342.     7.12.2 BY INDICATION, 2025-2035 (USD Billion)
  343.     7.12.3 BY SOURCE, 2025-2035 (USD Billion)
  344.     7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  345.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  346.     7.13.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  347.     7.13.2 BY INDICATION, 2025-2035 (USD Billion)
  348.     7.13.3 BY SOURCE, 2025-2035 (USD Billion)
  349.     7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  350.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  351.     7.14.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  352.     7.14.2 BY INDICATION, 2025-2035 (USD Billion)
  353.     7.14.3 BY SOURCE, 2025-2035 (USD Billion)
  354.     7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  355.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  356.     7.15.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  357.     7.15.2 BY INDICATION, 2025-2035 (USD Billion)
  358.     7.15.3 BY SOURCE, 2025-2035 (USD Billion)
  359.     7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  360.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  361.     7.16.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  362.     7.16.2 BY INDICATION, 2025-2035 (USD Billion)
  363.     7.16.3 BY SOURCE, 2025-2035 (USD Billion)
  364.     7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  365.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  366.     7.17.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  367.     7.17.2 BY INDICATION, 2025-2035 (USD Billion)
  368.     7.17.3 BY SOURCE, 2025-2035 (USD Billion)
  369.     7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  370.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  371.     7.18.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  372.     7.18.2 BY INDICATION, 2025-2035 (USD Billion)
  373.     7.18.3 BY SOURCE, 2025-2035 (USD Billion)
  374.     7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  375.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  376.     7.19.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  377.     7.19.2 BY INDICATION, 2025-2035 (USD Billion)
  378.     7.19.3 BY SOURCE, 2025-2035 (USD Billion)
  379.     7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  380.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  381.     7.20.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  382.     7.20.2 BY INDICATION, 2025-2035 (USD Billion)
  383.     7.20.3 BY SOURCE, 2025-2035 (USD Billion)
  384.     7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  385.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  386.     7.21.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  387.     7.21.2 BY INDICATION, 2025-2035 (USD Billion)
  388.     7.21.3 BY SOURCE, 2025-2035 (USD Billion)
  389.     7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  390.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  391.     7.22.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  392.     7.22.2 BY INDICATION, 2025-2035 (USD Billion)
  393.     7.22.3 BY SOURCE, 2025-2035 (USD Billion)
  394.     7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  395.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  396.     7.23.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  397.     7.23.2 BY INDICATION, 2025-2035 (USD Billion)
  398.     7.23.3 BY SOURCE, 2025-2035 (USD Billion)
  399.     7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  400.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  401.     7.24.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  402.     7.24.2 BY INDICATION, 2025-2035 (USD Billion)
  403.     7.24.3 BY SOURCE, 2025-2035 (USD Billion)
  404.     7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  405.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  406.     7.25.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  407.     7.25.2 BY INDICATION, 2025-2035 (USD Billion)
  408.     7.25.3 BY SOURCE, 2025-2035 (USD Billion)
  409.     7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  410.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  411.     7.26.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  412.     7.26.2 BY INDICATION, 2025-2035 (USD Billion)
  413.     7.26.3 BY SOURCE, 2025-2035 (USD Billion)
  414.     7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  415.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  416.     7.27.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  417.     7.27.2 BY INDICATION, 2025-2035 (USD Billion)
  418.     7.27.3 BY SOURCE, 2025-2035 (USD Billion)
  419.     7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  420.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  421.     7.28.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  422.     7.28.2 BY INDICATION, 2025-2035 (USD Billion)
  423.     7.28.3 BY SOURCE, 2025-2035 (USD Billion)
  424.     7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  425.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  426.     7.29.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  427.     7.29.2 BY INDICATION, 2025-2035 (USD Billion)
  428.     7.29.3 BY SOURCE, 2025-2035 (USD Billion)
  429.     7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  430.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  431.     7.30.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  432.     7.30.2 BY INDICATION, 2025-2035 (USD Billion)
  433.     7.30.3 BY SOURCE, 2025-2035 (USD Billion)
  434.     7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  435.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  436.     7.31.1
  437.   7.32 ACQUISITION/PARTNERSHIP
  438.     7.32.1

Healthcare Market Segmentation

Healthcare By Mechanism of Action (USD Billion, 2025-2035)

  • NF-B Inhibition
  • JAK/STAT Inhibition
  • Interleukin Inhibition
  • TNF- Inhibition

Healthcare By Indication (USD Billion, 2025-2035)

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Multiple Sclerosis

Healthcare By Source (USD Billion, 2025-2035)

  • Animal Origin
  • Plant Origin
  • Microbial Origin

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Injections
  • Oral
  • Topical

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $7,250 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions